23andMe to cut 40% of workforce, end therapeutics program
- Genetic-Testing company 23andMe will reduce its workforce by 40% and discontinue its therapeutics program to focus on its core consumer business.
- Approximately 200 employees will be affected, leading to expected annual savings of $35 million.
- Ms. Wojcicki stated, "We are taking these difficult but necessary actions as we restructure 23andMe...
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left11Leaning Right1Center20Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
L 34%
C 63%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage